Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates

Clinical Pharmacokinetics

Volumn 54, Issue 1, 2015, Pages 81-93

  Chen, Yuan ^a   Samineni, Divya ^a   Mukadam, Sophie ^a   Wong, Harvey ^a   Shen, Ben Quan ^a   Lu, Dan ^a   Girish, Sandhya ^a   Hop, Cornelis ^a   Jin, Jin Yan ^a   Li, Chunze ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; BRENTUXIMAB VEDOTIN; CITRULLINE; KETOCONAZOLE; MIDAZOLAM; RIFAMPICIN; UNCLASSIFIED DRUG; VALINE; CAC10-VCMMAE; IMMUNOCONJUGATES; MONOMETHYL AURISTATIN E; OLIGOPEPTIDES; RIFAMPIN;

AREA UNDER THE CURVE; ARTICLE; COMPUTER MODEL; CONJUGATE; DRUG CLEARANCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SIMULATION; COMPUTER SIMULATION; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL;

COMPUTER SIMULATION; DRUG INTERACTIONS; HUMANS; IMMUNOCONJUGATES; KETOCONAZOLE; MIDAZOLAM; MODELS, BIOLOGICAL; OLIGOPEPTIDES; RIFAMPIN;

EID: 84925815181     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0182-x     Document Type: Article

References (18)

1. Sasoon I, Blanc V. Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol. 2013;1045:1–27.
2. Trail PA. Antibody drug conjugates as cancer therapeutics. Antibodies. 2013;2:113–29.
3. Gorovits BA, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, Siguenza P. Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper. Bioanalysis. 2013;5:997–1006.
4. Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguera M. Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics. Bioanalysis. 2013;5:201–26.
5. US FDA, Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Application no. 125388 Orig1s000; BLA 125388 and 125399 brentuximab vedotin.
6. Lu D, Sahasranaman S, Zhang Y, Girish S. Strategies to address drug interaction potential for antibody–drug conjugates in clinical development. Bioanalysis. 2013;5:1115–30.
7. Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM, O’Connor OA. CYP3A-mediated drug–drug interaction potential and excretion of brentuximab vedotin, an antibody–drug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol. 2013;53:866–77.
8. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol. 1994;47:1469–79.
9. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos. 1999;27:1350–9.
10. Poulin P, Theil F-P. Prediction of pharmacokinetics prior to in vivo studies 1. Mechanistic-based prediction of volume of distribution. J Pharm Sci. 2002;91(1):129–56.
11. Berezhkovskiy LM. Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci. 2004;93:364–74.
12. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2005;95:1238–57.
13. Lin K, Tibbits J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res. 2012;92:2354–66.
14. Li D, Poon KA, Yu SF, Dere R, Go M, Lau J, Zheng B, Elkins K, Danilenko D, Kozak KR, Chan P, Chuh J, Shi X, Nazzal D, Fuh F, McBride J, Ramakrishnan V, de Tute R, Rawstron A, Jack AS, Deng R, Chu YW, Dornan D, Williams M, Ho W, Ebens A, Prabhu S, Polson AG. DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. Mol Cancer Ther. 2013;12:1255–65.
15. Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39:711–23.
16. European Medicines Agency. Assessment report: Adcetris. EMA/702390/2012. Procedure number EMEA/H/C/002455. 19 Jul 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002455/WC500135054.pdf. Accessed 12 Sep 2014.
17. Lu D, Agarwal P, Prabhu S, Nazzal D, Dere R, Saad O, et al. Pharmacokinetics of anti-CD22 and anti-CD79b antibody drug conjugates in relapsed or refractory B-cell non-Hodgkin’s lymphoma patients: results from phase 1 dose escalation studies. American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 5–9 March 2013; Indianapolis, IN.
18. Oncologic Drugs Advisory Committee. BLA number 125399 (relapsed or refractory systemic anaplastic large cell lymphoma).